DOCSLIB.ORG

Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule Author Manuscript Published OnlineFirst on February 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3511 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule Dependent Manner Authors: Matt L. Harlow1†,†††, Maggie H. Chasse2,†††, Elissa A. Boguslawski2, Katie M. Sorensen2, Jenna M. Gedminas2,5,6, Susan M. Kitchen-Goosen2, Scott B. Rothbart2, Cenny Taslim3, Stephen L. Lessnick3,4, Anderson S. Peck2††, Zachary B. Madaj2, Megan J. Bowman2‡, Patrick J. Grohar2,5,6* Affiliations: 1Department of Cancer Biology, Vanderbilt University, Nashville, TN, 37235, USA. 2Van Andel Research Institute, Grand Rapids, MI, 49503, USA. 3Center for Childhood Cancer and Blood Diseases, Nationwide Children’s Hospital Research Institute, Columbus, OH, USA. 4Division of Pediatric Hematology/Oncology/BMT, The Ohio State University College of Medicine, Columbus, OH, USA. 5Michigan State University, Department of Pediatrics, East Lansing, MI, USA. 6Helen DeVos Children’s Hospital, Division of Pediatric Hematology/Oncology, Grand Rapids, MI, USA. * [email protected], Phone: 616-234-5000. † Current Address: Dana-Farber Cancer Institute, Boston, MA, 02215, USA. ‡ Current Address: Ball Horticultural Company, West Chicago, IL, 60185, USA. †† Current Address: Bamf Health, Grand Rapids, MI ††† These authors contributed equally Key Words: Ewing sarcoma, EWS-FLI1, SWI/SNF, Pediatric Cancer, Sarcoma Running Title: Trabectedin inhibits EWS-FLI1 Financial Support: PJG is supported by a grant from the NIH (R01-CA188314). Additional support is from the NIH/NCI MHC (F31CA236300). The imaging portion of the study was supported by a Reach Award from Alex’s Lemonade Stand Foundation (PJG). The work is also supported by internal funds from the Van Andel Institute (PJG, SBR, ZVM, MJB). Additional support is from Hyundai Hope on Wheels (JMG), the NIH/NIGMS (R35GM124736)(SBR) and the NIH/NCI U54CA231641, R01CA183776 (SLL). Conflict of Interest: The authors declare no potential conflicts of interest. Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3511 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Purpose: The successful clinical translation of compounds that target specific oncogenic transcription factors will require an understanding of the mechanism of target suppression to optimize the dose and schedule of administration. We have previously shown trabectedin reverses the gene signature of the EWS-FLI1 transcription factor. In this report, we establish the mechanism of suppression and use it to justify the re-evaluation of this drug in the clinic in Ewing sarcoma patients. Experimental Design: We demonstrate a novel epigenetic mechanism of trabectedin using biochemical fractionation and chromatin immunoprecipitation sequencing (CHIP-Seq). We link the effect to drug schedule and EWS-FLI1 downstream target expression using confocal microscopy, qPCR, western blot analysis and cell viability assays. Finally, we quantitate target suppression within the 3-dimensional architecture of the tumor in vivo using 18F-FLT imaging. Results: Trabectedin evicts the SWI/SNF chromatin remodeling complex from chromatin and redistributes EWS-FLI1 in the nucleus leading to a marked increase in H3K27me3 and H3K9me3 at EWS-FLI1 target genes. These effects only occur at high concentrations of trabectedin leading to suppression of EWS-FLI1 target genes and a loss of cell viability. In vivo, low dose irinotecan is required to improve the magnitude, penetrance and duration of target suppression in the 3-dimensional architecture of the tumor leading to differentiation of the Ewing sarcoma xenograft into benign mesenchymal tissue. Conclusions: These data provide the justification to evaluate trabectedin in the clinic on a short infusion schedule in combination with low dose irinotecan with 18F-FLT PET imaging in Ewing sarcoma patients. Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3511 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Statement of Translational Relevance: This paper provides the basis for a clinical trial to evaluate trabectedin in combination with low dose irinotecan as an EWS-FLI1 targeted therapy. The clinical suppression of EWS-FLI1 has not been achieved despite a known dependence on this target for more than 20 years. In addition, trabectedin has failed in the disease in a phase II study. These data provide an explanation for the failed phase II, a schedule change that will improve the therapeutic suppression of EWS-FLI1 and evidence that low dose irinotecan improves the magnitude, penetrance and duration of EWS-FLI1 suppression in vivo. We demonstrate the utility of 18F- FLT to serve as a biomarker of EWS-FLI1 suppression in patients. In addition, we establish a novel mechanism of trabectedin as an inhibitor of the SWI/SNF chromatin remodeling complex which is mutated in approximately 25% of all human cancers. Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3511 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Introduction Oncogenic transcription factors are dominant oncogenes for a large number of leukemias and solid tumors in both the pediatric and adult populations (1-3). These proteins are challenging drug targets because the active site lacks a traditional druggable domain and most transcription factors interact with complex networks of proteins. Nevertheless, compounds that have successfully targeted specific transcription such as ATRA and arsenic trioxide in acute promyelocytic (APL) are effective in the clinic (4-6). Ewing sarcoma is a bone and soft tissue sarcoma that is absolutely dependent on the EWS-FLI1 transcription factor for cell survival (7). This fusion transcription factor, formed by the t(11;22)(q24;12) chromosomal translocation, both drives proliferation and blocks differentiation (8,9). EWS-FLI1 acts as a pioneer transcription factor and binds to repetitive regions of the genome called GGAA microsatellites (10-13). Once bound, the protein exhibits phase transition properties to establish these microsatellites as enhancers to drive gene expression (14). This requires a complex network of protein interactions and relies heavily on the ATP-dependent chromatin remodeling complex, SWI/SNF to maintain chromatin in an open state (14,15). Therefore, it is likely that reversal of EWS-FLI1 activity would lead to widespread changes in chromatin structure and restore the differentiation program. However, it is not clear if the effective targeting of EWS-FLI1 requires a blockade of SWI/SNF activity or if the pioneer transcription factor activity of EWS-FLI1 is reversible genome-wide. We have previously shown that the natural product trabectedin interferes with the activity of the EWS-FLI1 transcription factor (16). We showed that trabectedin reverses expression of the Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3511 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. EWS-FLI1 gene signature. In addition, we cloned EWS-FLI1 into another cellular context, induced an EWS-FLI1 driven promoter luciferase construct, and then rescued this induction with trabectedin (16). These findings were consistent with early preclinical and clinical experience with the drug which suggested a heightened sensitivity of Ewing sarcoma to trabectedin (17,18). Most notably, a patient with treatment-refractory Ewing sarcoma achieved a durable complete response with single agent trabectedin treatment in the phase I study. In contrast, the phase II study in Ewing sarcoma was negative and only 1 out of 10 patients responded to the drug (19). However, the drug was administered on a different schedule in the negative phase II study. Therefore, it is possible that a detailed understanding of the mechanism of EWS-FLI1 suppression by trabectedin would allow us to optimize the schedule of administration and achieve the therapeutic suppression of EWS-FLI1 in the clinic. Like many natural products, trabectedin has a complicated mechanism of action (20,21). The compound is known to generate DNA damage and poison various repair pathways, block specific transcription factors such as the FUS-CHOP transcription factor, and exert cytotoxicity with preference for specific cell types such as Tumor Associated Macrophages (TAM), myxoid liposarcoma cells, and Ewing sarcoma cells (22-24) In this study, we define the mechanism of EWS-FLI1 suppression to establish trabectedin as a bona fide EWS-FLI1 inhibitor. We show that the drug redistributes EWS-FLI1 within the nucleus and at the same time evicts the SWI/SNF chromatin remodeling complex to trigger an epigenetic switch, leading to global increases in H3K27me3 and H3K9me3 with preference
Load more

Recommended publications
  • Hippo/YAP Signaling Pathway: a Promising Therapeutic Target In
    Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia To cite this version: Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia. Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?. Can- cers, MDPI, 2020, 12 (3), pp.645. 10.3390/cancers12030645. inserm-03004096 HAL Id: inserm-03004096 https://www.hal.inserm.fr/inserm-03004096 Submitted on 13 Nov 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. cancers Review Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer and Franck Verrecchia * INSERM, UMR1238, Bone Sarcoma and Remodeling of Calcified Tissues, Nantes University, 44035 Nantes, France; [email protected] (S.M.); geoff[email protected] (G.D.); [email protected] (F.R.); [email protected] (B.B.-L.-R.) * Correspondence: [email protected]; Tel.: +33-244769116 Received: 4 February 2020; Accepted: 7 March 2020; Published: 10 March 2020 Abstract: Osteosarcoma and Ewing sarcoma are the most prevalent bone pediatric tumors.
    [Show full text]
  • FLI1 Gene Fli-1 Proto-Oncogene, ETS Transcription Factor
    FLI1 gene Fli-1 proto-oncogene, ETS transcription factor Normal Function The FLI1 gene provides instructions for making the FLI protein, which controls the activity (transcription) of genes. Transcription is the first step in the process of producing proteins. The FLI protein is part of a group of related proteins, called the Ets family of transcription factors, that control transcription. The FLI protein attaches (binds) to certain regions of DNA and turns on (activates) the transcription of nearby genes. The proteins produced from these genes control many important cellular processes, such as cell growth and division (proliferation), maturation (differentiation), and survival. The FLI protein is found primarily in blood cells and is thought to regulate their development. Health Conditions Related to Genetic Changes Ewing sarcoma Mutations involving the FLI1 gene cause a type of cancerous tumor known as Ewing sarcoma. These tumors develop in bones or soft tissues such as nerves and cartilage. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor, and Askin tumor. The mutations that cause these tumors are acquired during a person's lifetime and are present only in the tumor cells. This type of genetic change, called a somatic mutation, is not inherited. The most common mutation that causes Ewing sarcoma is a rearrangement (translocation) of genetic material between chromosome 11 and chromosome 22. This translocation, written as t(11;22), fuses part of the FLI1 gene on chromosome 11 with part of another gene called EWSR1 on chromosome 22, creating an EWSR1/FLI1 fusion gene.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Accompanies CD8 T Cell Effector Function Global DNA Methylation
    Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer, Benjamin G. Barwick, Benjamin A. Youngblood, Rafi Ahmed and Jeremy M. Boss This information is current as of October 1, 2021. J Immunol 2013; 191:3419-3429; Prepublished online 16 August 2013; doi: 10.4049/jimmunol.1301395 http://www.jimmunol.org/content/191/6/3419 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130139 Material 5.DC1 References This article cites 81 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/191/6/3419.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer,* Benjamin G. Barwick,* Benjamin A. Youngblood,*,† Rafi Ahmed,*,† and Jeremy M.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Supporting Information
    Supporting Information The deubiquitinase USP38 promotes NHEJ repair through regulation of HDAC1 activity and regulates cancer cell response to genotoxic insults Yongfeng Yang1,2, Chuanzhen Yang1，2, Tingting Li3, Shuyu Yu1,2,Tingting Gan4, Jiazhi Hu4, Jun Cui5,6, and Xiaofeng Zheng1,2,* 1 State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China. 2Department of Biochemistry and Molecular Biology, School of Life Sciences, Peking University, Beijing, China. 3State Key Laboratory of Proteomics, National Center of Biomedical Analysis, Institute of Basic Medical Sciences, Beijing, China. 4Department of Cell Biology, School of Life Sciences, Peking University, Beijing, China. 5Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China. 6Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, China. *To whom correspondence should be addressed. Xiaofeng Zheng, School of Life Sciences, Peking University, Beijing 100871, China. Tel: +86 10-6275-5712; Email: [email protected] Supplementary Materials and Methods: Antibodies and reagents Mouse monoclonal anti-Flag (F3165, RRID: AB_259529) antibodies, anti-HA (H9658, RRID: AB_260092) antibodies, and etoposide (E1383) were purchased from Sigma-Aldrich. Mouse monoclonal anti-Myc (M047-3, RRID: AB_591112), anti-histidine (D291–3, RRID: AB_10597733), and rabbit polyclonal anti-β-actin (PM053, RRID: AB_10598196) antibodies were purchased from MBL. Mouse monoclonal anti-H3 (BE3015) antibodies were purchased from EASYBIO. Mouse monoclonal anti-γH2AX (05–636, RRID: AB_309864) antibodies and MG132 (2772605) were purchased from Millipore. Mouse monoclonal anti-HDAC1 (sc-81598, RRID: AB_2118083) antibodies were purchased from Santa Cruz Biotechnology.
    [Show full text]
  • Screen for Multi-SUMO–Binding Proteins Reveals a Multi-SIM–Binding Mechanism for Recruitment of the Transcriptional Regulator ZMYM2 to Chromatin
    Screen for multi-SUMO–binding proteins reveals a multi-SIM–binding mechanism for recruitment of the transcriptional regulator ZMYM2 to chromatin Elisa Aguilar-Martineza, Xi Chena, Aaron Webbera, A. Paul Moulda, Anne Seifertb, Ronald T. Hayb, and Andrew D. Sharrocksa,1 aFaculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom; and bCentre for Gene Regulation and Expression, University of Dundee, Dundee DD1 5EH, United Kingdom Edited by James L. Manley, Columbia University, New York, NY, and approved July 17, 2015 (received for review May 20, 2015) Protein SUMOylation has emerged as an important regulatory human proteins containing two or more motifs corresponding event, particularly in nuclear processes such as transcriptional to the extended negatively charged amino acid-dependent control and DNA repair. In this context, small ubiquitin-like modifier SUMOylation motif (NDSM) (13) Thus, there is a huge poten- (SUMO) often provides a binding platform for the recruitment of tial for widespread multi-SUMOylation of proteins to occur. proteins via their SUMO-interacting motifs (SIMs). Recent discoveries Indeed, several of these proteins have been shown to be point to an important role for multivalent SUMO binding through SUMOylated on multiple sites, including megakaryoblastic leu- multiple SIMs in the binding partner as exemplified by poly- kemia (translocation) 1 (MKL1) (14), CREB-binding protein SUMOylation acting as a binding platform for ubiquitin E3 ligases (CBP) (15), and PEA3/ETV4 (16). Furthermore, two recent such as ring finger protein 4. Here, we have investigated whether proteomic studies emphasize the potential for more widespread other types of protein are recruited through multivalent SUMO multi-SUMOylation as they found that a large proportion of all interactions.
    [Show full text]
  • Expression Profiling of RE1-Silencing Transcription Factor (REST), REST
    JBUON 2016; 21(4): 964-972 ISSN: 1107-0625, online ISSN: 2241-6293 • www.jbuon.com E-mail: [email protected] ORIGINAL ARTICLE Expression profiling of RE1-silencing transcription factor (REST), REST corepressor 1 (RCOR1), and Synapsin 1 (SYN1) genes in human gliomas Musteyde Yucebas1, Sunde Yilmaz Susluer1, Hasan Onur Caglar2, Tugce Balci1, Z. Ozlem Dogan Sigva1, Taner Akalin3, Nezih Oktar4, Tayfun Dalbasti4, Cigir Biray Avci1, Cumhur Gunduz1 1Ege University Medical Faculty, Department of Medical Biology, Bornova, Izmir; 2Ege University, Health Science Institute, Department of Stem Cell, Bornova, Izmir; 3Ege University Medical Faculty, Department of Pathology, Bornova, Izmir; 4Ege University, Medical Faculty, Department of Neurosurgery, Bornova, Izmir, Turkey Summary Purpose: The repressor element 1 (RE-1) silencing tran- Results: Means of relative expression for REST were as scription factor (REST) is a transcription factor which re- follows: 0.7898, 0.7606, and 0.7318 in DA, AO, and GBM presses the expression of neuronal differentiation-related groups, respectively. For RCOR1, expression means in DA, genes including SYN1 gene. CoREST, encoded by RCOR1 AO, and GBM groups were 0.7203, 0.7334, and 0.7230, re- gene, binds to the REST protein for remodeling of chroma- spectively. SYN1 expression means were as follows: 0.3936, tin structure. Although there is a relation among REST, 0.3192, and 0.3197 in DA, AO, and GBM groups, respective- RCOR1, and SYN1 genes, the role of these genes in glioma ly. Neither gain nor loss of copy numbers were detected for tumors is still unclear. In this study, expressions of REST, REST and RCOR1 genes in all groups.
    [Show full text]
  • Supplementary Figure Legends
    1 Supplementary Figure legends 2 Supplementary Figure 1. 3 Experimental workflow. 4 5 Supplementary Figure 2. 6 IRF9 binding to promoters. 7 a) Verification of mIRF9 antibody by site-directed ChIP. IFNβ-stimulated binding of IRF9 to 8 the ISRE sequences of Mx2 was analyzed using BMDMs of WT and Irf9−/− (IRF9-/-) mice. 9 Cells were treated with 250 IU/ml of IFNβ for 1.5h. Data represent mean and SEM values of 10 three independent experiments. P-values were calculated using the paired ratio t-test (*P ≤ 11 0.05; **P ≤ 0.01, ***P ≤ 0.001). 12 b) Browser tracks showing complexes assigned as STAT-IRF9 in IFNγ treated wild type 13 BMDMs. Input, STAT2, IRF9 (scale 0-200). STAT1 (scale 0-150). 14 15 Supplementary Figure 3. 16 Experimental system for BioID. 17 a) Kinetics of STAT1, STAT2 and IRF9 synthesis in Raw 264.7 macrophages and wild type 18 BMDMs treated with 250 IU/ml as indicated. Whole-cell extracts were tested in western blot 19 for STAT1 phosphorylation at Y701 and of STAT2 at Y689 as well as total STAT1, STAT2, 20 IRF9 and GAPDH levels. The blots are representative of three independent experiments. b) 21 Irf9-/- mouse embryonic fibroblasts (MEFs) were transiently transfected with the indicated 22 expression vectors, including constitutively active IRF7-M15. One day after transfection, 23 RNA was isolated and Mx2 expression determined by qPCR. c) Myc-BirA*-IRF9 transgenic 24 Raw 264.7 were treated with increasing amounts of doxycycline (dox) (0,2µg/ml, 0,4µg/ml, 25 0,6µg/ml, 0,8µg/ml, 1mg/ml) and 50µM biotin.
    [Show full text]
  • Whole Transcriptomic Expression Differences in EBV Immortalized Versus Primary B-Cells
    W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 12-2010 Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B-Cells Dolores Huberts College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Biology Commons Recommended Citation Huberts, Dolores, "Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B- Cells" (2010). Undergraduate Honors Theses. Paper 347. https://scholarworks.wm.edu/honorstheses/347 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B-Cells A thesis submitted in partial fulfillment of the requirement for the degree of Bachelor of Science with Honors in Biology from the College of William and Mary in Virginia By Dolores Huberts Accepted for Honors ________________________________________ Lizabeth A. Allison, Director ________________________________________ Matthew Wawersik ________________________________________ Drew LaMar ________________________________________ Beverly Sher Williamsburg, Virginia December 17, 2010 ABSTRACT The Epstein–Barr Virus (EBV) is a human gamma herpes virus that infects more than 90% of the human population worldwide. It is commonly known in the US as the cause of Infectious Mononucleosis, and around the world as the cause of nasopharyngeal carcinoma and malignant lymphomas such as non-Hodgkin lymphoma, endemic Burkett’s lymphoma and Hodgkin lymphoma. Additionally, the EBV is used to immortalize cells to create cell lines for in-vitro studies.
    [Show full text]
  • Characterization of the Zinc Finger Proteins ZMYM2 and ZMYM4 As
    www.nature.com/scientificreports OPEN Characterization of the zinc fnger proteins ZMYM2 and ZMYM4 as novel B-MYB binding proteins Hannah Cibis, Abhiruchi Biyanee, Wolfgang Dörner, Henning D. Mootz & Karl-Heinz Klempnauer✉ B-MYB, a highly conserved member of the MYB transcription factor family, is expressed ubiquitously in proliferating cells and plays key roles in important cell cycle-related processes, such as control of G2/M- phase transcription, cytokinesis, G1/S-phase progression and DNA-damage reponse. Deregulation of B-MYB function is characteristic of several types of tumor cells, underlining its oncogenic potential. To gain a better understanding of the functions of B-MYB we have employed afnity purifcation coupled to mass spectrometry to discover novel B-MYB interacting proteins. Here we have identifed the zinc-fnger proteins ZMYM2 and ZMYM4 as novel B-MYB binding proteins. ZMYM4 is a poorly studied protein whose initial characterization reported here shows that it is highly SUMOylated and that its interaction with B-MYB is stimulated upon induction of DNA damage. Unlike knockdown of B-MYB, which causes G2/M arrest and defective cytokinesis in HEK293 cells, knockdown of ZMYM2 or ZMYM4 have no obvious efects on the cell cycle of these cells. By contrast, knockdown of ZMYM2 strongly impaired the G1/S-phase progression of HepG2 cells, suggesting that ZMYM2, like B-MYB, is required for entry into S-phase in these cells. Overall, our work identifes two novel B-MYB binding partners with possible functions in the DNA-damage response and the G1/S-transition. Te highly conserved MYB proto-oncogene family member B-MYB is ubiquitously expressed in proliferat- ing cells where it acts as an essential cell cycle-regulated transcription factor1,2.
    [Show full text]